Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.
Ann Oncol
; 28(11): 2899, 2017 11 01.
Article
in En
| MEDLINE
| ID: mdl-27634692
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Language:
En
Journal:
Ann Oncol
Journal subject:
NEOPLASIAS
Year:
2017
Type:
Article